Progress in experimental phenylketonuria: a critical review.
Experimental progress in the development of an accurate and useful model of phenylketonuria (PKU) during the last 15 years is reviewed in detail. From this review it is clear that the recent emergence of models using the combined administration of phenylalanine (phe) and p-chlorophenylalanine (PCPA) constitutes a major success that lays the groundwork for future research into the pathogenesis and treatment of PKU. Biochemical evidence on the pathophysiology of PKU is also briefly reviewed in the context of the behavioral and biochemical adequacy of the models used. It appears that in the past biochemical investigations into PKU have been impaired by use of inadequate models, a situation that should now change if the best of the phe-PCPA models are more widely adopted. New trends in PKU research involve the role of large neutral amino acids other than phe as potential aids in the treatment of PKU and the appearance of a new model based on the use of alpha-methylphenylalanine (AMPhe) combined with phe. It appears that PKU research may be on the brink of a new and productive era as investigations into these promising areas unfold and as new emerge through the full utilization of existing models.
D000015:Abnormalities, Multiple / Q000235:genetics; D000818:Animals; D004195:Disease Models, Animal; D004734:Energy Metabolism; D005260:Female; D010134:Fenclonine; D005971:Glutamates / Q000378:metabolism; D006801:Humans; D051379:Mice; D009186:Myelin Sheath / Q000378:metabolism; D010649:Phenylalanine / Q000031:analogs & derivatives; D010661:Phenylketonurias / Q000139:chemically induced / Q000235:genetics / Q000628:therapy; D011247:Pregnancy; D011248:Pregnancy Complications; D014176:Protein Biosynthesis; D011736:Pyridoxine / Q000378:metabolism; D012701:Serotonin / Q000172:deficiency
D005971:Glutamates; D012701:Serotonin; C012436:alpha-methylphenylalanine; D010649:Phenylalanine; D011736:Pyridoxine; D010134:Fenclonine